Investigational drug BLEX 404 with gemcitabine for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an investigational oral liquid called BLEX 404 combined with the standard chemotherapy gemcitabine to see if it is more effective in treating advanced pancreatic cancer. The goal is to help slow cancer growth and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 80 years old.
- You have advanced or metastatic pancreatic cancer that cannot be removed by surgery.
- Your physical fitness level is 1 or 2 on the ECOG scale (able to walk and do light work).
- Your blood cell counts and liver and kidney function are within acceptable ranges.
- You have not previously received gemcitabine chemotherapy.
- You are planning to take gemcitabine as your only chemotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug (LM-302) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that has progressed after initial treatment. The goal is to see if this combination can slow down or shrink the cancer.
This trial tests AK104 (an antibody medicine) given with standard chemotherapy as the first treatment for advanced pancreatic ductal cancer. It aims to see whether this combination works better and is safe for people with cancer that has spread or is advanced.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This study tests a new treatment for people with stage 4 pancreatic cancer who haven't yet had any treatment for advanced disease. The goal is to see if the new treatment can help shrink or control the cancer.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.